3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
8
Phase 2
6
Phase EARLY_PHASE1
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
91
Melanoma
74
Squamous Cell Carcinoma of Head and Neck
47
Neoplasms
44
Neoplasm Metastasis
43
Lung Neoplasms
37
Carcinoma, Renal Cell
36
Colorectal Neoplasms
35
Breast Neoplasms
34
Triple Negative Breast Neoplasms
30
Stomach Neoplasms
26
Carcinoma, Transitional Cell
26
Ovarian Neoplasms
25
Head and Neck Neoplasms
24
Parkinson Disease 4, Autosomal Dominant Lewy Body
21
Esophageal Neoplasms
20
Pancreatic Neoplasms
18
Uterine Cervical Neoplasms
17
Urinary Bladder Neoplasms
16
Endometrial Neoplasms
16
Small Cell Lung Carcinoma
15
Carcinoma, Hepatocellular
15
Sarcoma
13
Recurrence
12
Glioblastoma
12
Carcinoma
12
Prostatic Neoplasms
11
Lymphoma
11
Mesothelioma
9
Carcinoma, Merkel Cell
9
Interventions
Cyclophosphamide
25
Rituximab
22
fludarabine
14
Lenalidomide
10
Vincristine
8
Doxorubicin
8
Prednisone
7
Etoposide
7
fludarabine phosphate
6
Immunotherapy, Adoptive
5
polatuzumab vedotin
4
Cytarabine
4
CT-P10
4
Bendamustine Hydrochloride
4
Antigens, CD19
4
tocilizumab
3
Gemcitabine
3
Dexamethasone
3
Carboplatin
3
venetoclax
2
veltuzumab
2
prednylidene
2
ofatumumab
2
obinutuzumab
2
ixazomib
2
ibrutinib
2
etoposide phosphate
2
deltacortene
2
carmustine, poliferprosan 20 drug combination
2
acalabrutinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lymphoma, B-Cell
×
pembrolizumab
×
Clear all
NCT03598608
2026-02-05
MK-4280-003
Merck Sharp & Dohme LLC
Phase 1/2
Completed
137 enrolled